WASHINGTON -- (TheStreet) The stock market's rising after health care reform became law is good for American businesses of all sizes.
There is nothing bad about attempting to offer businesses a pool of healthier employees. Health care costs are out of control, and an effort to restrain employee benefit costs is worth trying. While this reform will not be as good for American business' global competitiveness as a single-payer system, it is a step in the right direction.
Four stocks on the rise that expect to benefit from the filling of the prescription drug "doughnut hole" include Pfizer (PFE), Mylan (MYL), Watson Pharmaceuticals (WPI) and Eli Lilly (LLY). Pfizer, Watson, and Lilly are all rated at 'Buy' by our stock model. Mylan is unrated at this time.
Select the service that is right for you!COMPARE ALL SERVICES
- $2.5+ million portfolio
- Large-cap and dividend focus
- Intraday trade alerts from Cramer
- Weekly roundups
Access the tool that DOMINATES the Russell 2000 and the S&P 500.
- Buy, hold, or sell recommendations for over 4,300 stocks
- Unlimited research reports on your favorite stocks
- A custom stock screener
- Upgrade/downgrade alerts
- Diversified model portfolio of dividend stocks
- Alerts when market news affect the portfolio
- Bi-weekly updates with exact steps to take - BUY, HOLD, SELL
- Real Money + Doug Kass Plus 15 more Wall Street Pros
- Intraday commentary & news
- Ultra-actionable trading ideas
- 100+ monthly options trading ideas
- Actionable options commentary & news
- Real-time trading community
- Options TV